Friday, July 10, 2026

Drug profile · INN

norelgestromin

norelgestromin (EVRA) is a progesterone receptor agonist.

EMA: approved Genito-urinary system and sex hormones (G03) G03AA13
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — norelgestromin
Class
Genito-urinary system and sex hormones (G03)
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

norelgestromin (EVRA) is a progesterone receptor agonist.

Key facts

INN norelgestromin
Brand EVRA
Mechanism Progesterone receptor agonist
Target Progesterone receptor
Therapeutic class Genito-urinary system and sex hormones (G03)
ATC code G03AA13

Mechanism of action

Progesterone receptor agonist

Primary target: Progesterone receptor

Approval history

Authority Status Date
EMA approved

Related & competitor drugs

  1. apomorphine Genito-urinary system and sex hormones (G04)
  2. desogestrel Progesterone receptor agonist
  3. medroxyprogesterone acetate Progesterone receptor agonist
  4. megestrol acetate Progesterone receptor agonist
  5. mirabegron Genito-urinary system and sex hormones (G04)
  6. norethindrone Progesterone receptor agonist

Frequently asked questions

What is norelgestromin?

norelgestromin (EVRA) is a progesterone receptor agonist.

What is the brand name for norelgestromin?

EVRA is a marketed brand name for norelgestromin. Check FDA Drugs@FDA for the current US label holder and prescribing information.